IRVINE, Calif., March 28, 2020 /PRNewswire/ — Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced it will temporarily pause new enrollments in its active pivotal clinical trials of transcatheter mitral and tricuspid therapies, in response to the urgent COVID-19 response […]
Other News
MyoKardia Announces Mavacamten Treatment Well Tolerated and Significantly Reduced Biomarkers of Cardiac Injury and Wall Stress in Non-Obstructive Hypertrophic Cardiomyopathy Patients
MAVERICK-HCM Phase 2 Clinical Trial Results Consistent with Tolerability Observations from Prior Studies of Mavacamten Improvement in NT-proBNP and Troponin Levels Support Future Development in Non-Obstructive HCM and Heart Failure with Preserved Ejection Fraction (HFpEF) MyoKardia to Host Webcast Conference Call at 4:30 p.m. EDT BRISBANE, Calif., March 30, 2020 […]
Resverlogix Announces Publication of Key Apabetalone Study BETonMACE in the Journal of the American Medical Association
Announces publication of accompanying JAMA editorial highlighting important secondary endpoints including congestive heart failure Apabetalone development program moving toward next study to enable a New Drug Application filing CALGARY, Alberta, March 30, 2020 (GLOBE NEWSWIRE) — Resverlogix Corp. (“Resverlogix” or the “Company”) (TSX:RVX) announced today the recent publication of an […]
Medtronic Onyx ONE Clear Study of One-Month Dual-Antiplatelet Therapy in High Bleeding Risk Stent Patients Beats Performance Goal
First Study in the U.S. and Japan to Report Results on One-Month DAPT Duration in High Bleeding Risk Patients with Current-Generation DES DUBLIN, March 30, 2020 (GLOBE NEWSWIRE) — Medtronic plc (NYSE:MDT) today announced positive results of the Onyx ONE Clear Study that evaluated Resolute Onyx DES in high bleeding risk (HBR) […]
PhaseBio Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Recent Business Highlights
Recently Initiated PB2452 Phase 3 Trial for the Reversal of the Antiplatelet Effects of Ticagrelor Received FDA Breakthrough Therapy Designation and EMA PRIME Designation for PB2452 Secured PB2452 Financing and Co-Development Collaboration with SFJ Pharmaceuticals® MALVERN, Pa. and SAN DIEGO, March 30, 2020 (GLOBE NEWSWIRE) — PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a […]
Bellerophon Therapeutics Announces First Patient Treated with INOpulse® Inhaled Nitric Oxide Therapy for COVID-19
WARREN, N.J., March 30, 2020 (GLOBE NEWSWIRE) — Bellerophon Therapeutics, Inc. (Nasdaq: BLPH), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced that expanded access treatment with the INOpulse® inhaled nitric oxide system (iNO) was initiated for the first time in a patient with a diagnosis […]
Esperion Announces Three Data Presentations of the NEXLETOL™ (bempedoic acid) Tablet and the NEXLIZET™ (bempedoic acid and ezetimibe) Tablet at the American College of Cardiology’s 69th Annual Scientific Session Together with World Congress of Cardiology (ACC.20/WCC)
ANN ARBOR, Mich., March 28, 2020 (GLOBE NEWSWIRE) — Esperion (NASDAQ:ESPR) today announced that two pooled analyses from four Phase 3 clinical trials of NEXLETOL and results from the Phase 2 (1002-058) study of NEXLIZET were presented at the American College of Cardiology’s 69th Scientific Session Together with World Congress of […]
Landmark SPYRAL HTN-OFF MED Pivotal Trial Shows Superiority for Renal Denervation in Patients with High Blood Pressure Compared to Sham Procedure
ACC.20/WCC: Study Finds Significant Blood Pressure Reductions Achieved with RDN in Absence of Anti-Hypertensive Medication Medtronic Receives FDA “Breakthrough Device Designation” for Symplicity Spyral™ Renal Denervation System DUBLIN, March 29, 2020 (GLOBE NEWSWIRE) — Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced first-ever clinical data from the SPYRAL HTN-OFF MED […]
Analytics 4 Life® Presents Early Data Supporting Novel, Non-Invasive Method of Predicting Elevated Left Ventricular Pressure at the American College of Cardiology’s (ACC) 69th Annual Scientific Session Together with World Congress of Cardiology
RESEARCH TRIANGLE PARK, N.C. & TORONTO–(BUSINESS WIRE)–Analytics 4 Life, a digital health company dedicated to improving existing diagnostic pathways, today reported data for the first time on its heart failure research at the American College of Cardiology’s (ACC) 69th Annual Scientific Session Together with World Congress of Cardiology. The data suggest […]
Avive Solutions’ AED Machine Learning Algorithm Exceeds American Heart Association’s Performance Recommendations
SAN FRANCISCO–(BUSINESS WIRE)–Avive Solutions, Inc (“Avive” or the “Company”), a developer of a next-generation Automated External Defibrillator (“AED”) and innovative cardiac arrest response solutions, was selected to present a study on a novel machine-learning algorithm for arrhythmia classification via a podium presentation at the American College of Cardiology Conference 2020. The study […]
Recent
New HFSA Scientific Statement Provides Practical Guidance for Managing Heart Failure with Mildly Reduced Ejection Fraction
Sonorous Neurovascular Receives FDA 510(k) Clearance for BosCATH™ Neurovascular Catheter
Microbot Medical® Welcomes Updated Occupational Protection Guidelines from Leading Medical Societies, Strengthening Commercial Position of LIBERTY®
Popular
- No commented posts yet